Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma

Starting soon · Phase 2/Phase 3

Conditions studied: Recurrent Glioblastoma, IDH-Wildtype

In brief

This study is designed as a multi-center, randomized, open-label trial to evaluate the efficacy of Cerebraca Wafer in patients with recurrent glioblastoma. Cerebraca Wafer is intended for use in recurrent glioblastoma as an adjunct to surgery (followed by standard-of-care temozolomide), demonstrating potential to improve outcomes in this serious and life-threatening condition

Key facts

Study ID

NCT07349693

Run by

Everfront Biotech Co., Ltd.

People needed

175

Starts

2026-11-01

Expected to finish

2030-12-01

Last updated by the study team

2026-01-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Legorreta Cancer Center Warren Alpert Medical School of Brown University — Providence, Rhode Island, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.